Neovasc Provides Corporate Update Following Clinical Data Release
September 20, 2022 09:05 ET
|
Neovasc, Inc.
New Data Presented on the Neovasc Reducer™ in Patients With Microvascular Disease VANCOUVER and MINNEAPOLIS, Sept. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the...
Neovasc Reducer System Receives First National Reimbursement in Europe
June 07, 2021 09:05 ET
|
Neovasc, Inc.
NHS England Provides National Coverage VANCOUVER and MINNEAPOLIS, June 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today...
Neovasc Responds to FDA Not-Approvable Letter Regarding Neovasc Reducer™
January 15, 2021 16:59 ET
|
Neovasc, Inc.
VANCOUVER and MINNEAPOLIS, Jan. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has received a “not-approvable”...